Startups
LiberaBio is a preclinical stage biotech that develops new oncology treatments based on the proprietary MPN technology. This nanotechnology actively targets tumor and metastatic cells and delivers small and large molecules to on-surface or intracellular targets. The company is creating new treatments by delivering novel antibodies targeting intracellular oncoproteins.
Overview
Location
Spain, Galicia, Santiago de Compostela
Employees
1-10
Founded date
2018
Mentions in press and media 2
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 24, 2022 | XesGalicia invierte €289.500 en Libera Bio a través de Galicia InnovaTech | 24/01/2022 Nota de prensa XESGALICIA INVIERTE EN LIBERA BIO PARA QUE PUEDA SEGUIR AVANZANDO EN EL DESARROLLO DE MEDICAMENTOS BIOLÓGICOS CONTRA EL CÁNCER. La gestora de capital riesgo (venture capital) XesGalicia participará, a través de ... |
Reviews 0
FAQ about LiberaBio
When was LiberaBio founded?
LiberaBio was founded in 2018.
What has the press written about LiberaBio?
Parsers VC has collected 2 articles mentioning LiberaBio, among them “XesGalicia invierte €289.500 en Libera Bio a través de Galicia InnovaTech” (Jan 24, 2022).
Is LiberaBio still active?
Yes, LiberaBio is active; its latest activity on Parsers VC dates from Jul 19, 2022.